Aveanna Healthcare (NASDAQ:AVAH) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Aveanna Healthcare (NASDAQ:AVAH) released its earnings results on Thursday. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.08, FiscalAI reports. Aveanna Healthcare had a net margin of 3.29% and a negative return on equity of 103.46%. The firm had revenue of $621.94 million during the quarter, compared to analyst estimates of $578.57 million. Aveanna Healthcare updated its FY 2025 guidance to EPS.

Aveanna Healthcare Stock Performance

NASDAQ AVAH traded up $0.12 on Friday, reaching $8.75. 1,381,278 shares of the stock traded hands, compared to its average volume of 1,771,923. Aveanna Healthcare has a 12 month low of $3.67 and a 12 month high of $10.32. The company has a market cap of $1.83 billion, a price-to-earnings ratio of 24.31 and a beta of 2.04. The company has a fifty day moving average price of $8.86 and a 200-day moving average price of $6.50.

Insider Activity

In related news, major shareholder Robert M. Williams, Jr. sold 10,000,000 shares of Aveanna Healthcare stock in a transaction dated Tuesday, October 21st. The stock was sold at an average price of $9.00, for a total value of $90,000,000.00. Following the completion of the sale, the insider directly owned 386,284 shares in the company, valued at $3,476,556. The trade was a 96.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Paul R. Vigano sold 10,000,000 shares of the stock in a transaction dated Tuesday, October 21st. The stock was sold at an average price of $9.00, for a total transaction of $90,000,000.00. Following the transaction, the insider owned 386,284 shares in the company, valued at approximately $3,476,556. The trade was a 96.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 32,597,968 shares of company stock worth $293,381,712. Company insiders own 7.80% of the company’s stock.

Hedge Funds Weigh In On Aveanna Healthcare

A number of large investors have recently bought and sold shares of the business. AQR Capital Management LLC boosted its position in Aveanna Healthcare by 21.2% during the 1st quarter. AQR Capital Management LLC now owns 26,280 shares of the company’s stock valued at $142,000 after acquiring an additional 4,602 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Aveanna Healthcare by 8.3% during the first quarter. Goldman Sachs Group Inc. now owns 339,853 shares of the company’s stock valued at $1,842,000 after purchasing an additional 25,974 shares in the last quarter. Jane Street Group LLC grew its stake in Aveanna Healthcare by 522.0% in the first quarter. Jane Street Group LLC now owns 75,081 shares of the company’s stock valued at $407,000 after purchasing an additional 63,010 shares during the last quarter. Creative Planning raised its holdings in Aveanna Healthcare by 15.1% in the second quarter. Creative Planning now owns 47,025 shares of the company’s stock worth $246,000 after purchasing an additional 6,171 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Aveanna Healthcare by 65.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 158,265 shares of the company’s stock valued at $828,000 after buying an additional 62,348 shares in the last quarter. Institutional investors own 87.96% of the company’s stock.

Wall Street Analysts Forecast Growth

AVAH has been the subject of several analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Aveanna Healthcare in a research note on Wednesday, October 8th. UBS Group increased their price target on Aveanna Healthcare from $9.00 to $9.50 and gave the stock a “neutral” rating in a report on Friday. Barclays raised Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $5.50 to $9.50 in a research note on Tuesday, August 19th. Wall Street Zen raised Aveanna Healthcare from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Finally, Jefferies Financial Group increased their target price on Aveanna Healthcare from $11.00 to $12.50 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. Three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $10.07.

About Aveanna Healthcare

Aveanna Healthcare Holdings Inc, a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities.